Richard G. Hamermesh, Raju Kucherlapati, Rachel Gordon
Harvard Business School (810066-PDF-ENG)
November 06, 2009
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, which was developed to fight metastatic colon cancer, had been rejected. This was particularly surprising news, as a similar competitor drug had received approval several years earlier. Additionally, Vectibix received approval from the Food and Drug Administration in 2006. In additional studies, Amgen has found that Vectibix is only effective in the 60% of the population who have a particular genetic marker. Given this development, what should Amgen’s strategy for Vectibix look like in both Europe and the United States?
We don‘t have the case solution, but we pay up to $50 for yours!
- Set a reminder to receive an email after your university‘s case study deadline.
- Upload your case study solution. We will review it for quality.
- Get your money via PayPal or to your bank account.